GURUFOCUS.COM » STOCK LIST » Industrials » Industrial Distribution » Sichuan Goldstone Asia Pharmaceutical Inc (SZSE:300434) » Definitions » Change In Receivables

Sichuan Goldstone Asia Pharmaceutical (SZSE:300434) Change In Receivables : ¥0 Mil (TTM As of Mar. 2025)


View and export this data going back to 2015. Start your Free Trial

What is Sichuan Goldstone Asia Pharmaceutical Change In Receivables?

Sichuan Goldstone Asia Pharmaceutical's change in receivables for the quarter that ended in Mar. 2025 was ¥0 Mil. It means Sichuan Goldstone Asia Pharmaceutical's Accounts Receivable stayed the same from Dec. 2024 to Mar. 2025 .

Sichuan Goldstone Asia Pharmaceutical's change in receivables for the fiscal year that ended in Dec. 2024 was ¥-34 Mil. It means Sichuan Goldstone Asia Pharmaceutical's Accounts Receivable increased by ¥34 Mil from Dec. 2023 to Dec. 2024 .

Sichuan Goldstone Asia Pharmaceutical's Accounts Receivable for the quarter that ended in Mar. 2025 was ¥89 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Sichuan Goldstone Asia Pharmaceutical's Days Sales Outstanding for the three months ended in Mar. 2025 was 27.97.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Sichuan Goldstone Asia Pharmaceutical's liquidation value for the three months ended in Mar. 2025 was ¥26 Mil.


Sichuan Goldstone Asia Pharmaceutical Change In Receivables Historical Data

The historical data trend for Sichuan Goldstone Asia Pharmaceutical's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sichuan Goldstone Asia Pharmaceutical Change In Receivables Chart

Sichuan Goldstone Asia Pharmaceutical Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Change In Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 190.15 -220.68 -109.55 88.62 -34.45

Sichuan Goldstone Asia Pharmaceutical Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Sichuan Goldstone Asia Pharmaceutical Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sichuan Goldstone Asia Pharmaceutical  (SZSE:300434) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Sichuan Goldstone Asia Pharmaceutical's Days Sales Outstanding for the quarter that ended in Mar. 2025 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=89.351/291.494*91
=27.97

2. In Ben Graham's calculation of liquidation value, Sichuan Goldstone Asia Pharmaceutical's accounts receivable are only considered to be worth 75% of book value:

Sichuan Goldstone Asia Pharmaceutical's liquidation value for the quarter that ended in Mar. 2025 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=307.754-449.881+0.75 * 89.351+0.5 * 202.87
=26

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sichuan Goldstone Asia Pharmaceutical Change In Receivables Related Terms

Thank you for viewing the detailed overview of Sichuan Goldstone Asia Pharmaceutical's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


Sichuan Goldstone Asia Pharmaceutical Business Description

Traded in Other Exchanges
N/A
Address
8 Jiayuan Road, 8th Floor, District A1, Dadi Xinguanghua Plaza, Chengdu, CHN, 610072
Sichuan Goldstone Asia Pharmaceutical Inc is engaged in development and application of steel-reinforced plastic composite pipe technology, providing customers with steel-reinforced plastic composite pipes from pipe structure, production process to construction technology. The company is also engaged in research and development, production and sales of medicines and health products.
Executives
Zheng Zhi Yong Director
Wei Bao Kang Directors, executives
Kuai Yi Xi Director
Chen Shao Jiang Executives
Lai Xing Feng Supervisors
Lin Qiang Directors, Directors, and Executives
Fu Hai Ying Directors, executives
Wang Shou Lun Supervisors
Li Run Xiu Supervisors

Sichuan Goldstone Asia Pharmaceutical Headlines

No Headlines